+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Graft Versus Host Disease (GvHD) - Epidemiology Forecast - 2032

  • PDF Icon

    Report

  • 102 Pages
  • August 2023
  • Region: Global
  • DelveInsight
  • ID: 4330796

Quick Summary:

In the evolving landscape of graft-versus-host disease management, staying abreast of current and projected epidemiological trends is vital. Developed for decision-makers, this Graft vs. Host Disease - Epidemiology Forecast - 2032 report provides a detailed panorama on the incidence and prevalence of this severe complication of allogeneic stem cell transplantation in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Armed with historical and forecasted data, the report elucidates the severity and organ-specific grading of graft-versus-host disease cases. Moreover, recognizing the significant mortality rate, the report also presents insights on the number of living patients receiving or eligible for treatment. This comprehensive knowledge is paramount for informed decision-making and strategic planning in the quest to tackle graft-versus-host disease.

With a deep dive on the burden and diagnosis rates, and factors contributing to epidemiology changes, this report offers an essential tool for understanding the disease and planning better interventions. Its strength lies in the ten-year forecast and comprehensive epidemiology segmentation, providing a future-ready approach to deal with this major challenge in transplantation.

Key Highlights

  • Graft-versus-host disease is a potentially serious complication of allogeneic stem cell transplantation.
  • Total allogenic transplant cases of graft-versus-host disease in the 7MM range from ~24,440 in 2022 to ~29,600 in 2032.
  • Graft-versus-host disease is categorized into two types: acute and chronic graft-versus-host disease. In the 7MM, the acute graft-versus-host disease incident cases were ~10,340 in 2022, which are likely to increase to ~12,360 by 2032. Furthermore, in the 7MM, the 5-year prevalence of chronic graft-versus-host disease was ~23,080 in 2022, which is likely to increase to ~26,300 cases by 2032.
  • Three major organs targeted by acute type are the skin (~71%), gastrointestinal tract (~79%), and liver (~21%). An assessment of the degree of involvement of these organs determines the severity of acute graft-versus-host disease.
  • In the US, the grading-specific incident cases of acute graft-versus-host disease for Grade B, Grade C, and Grade D were ~3,140, ~1,280, and ~600, respectively, in 2022, which are likely to increase to ~3,930, ~1,600, and ~760, respectively, by 2032.
  • The overall severity of chronic graft-versus-host disease is classified as mild, moderate, or severe based on organ-specific grading (number of organs and severity). Approximately ~45% of 5-year prevalent cases of chronic graft-versus-host disease belong to the moderate category.
  • Skin (~59%), oral mucosa (~53%), eyes (~53%), lungs (~43%), liver (~29%), joints and fascia (~28%), and gastrointestinal (~23%) are the most often affected organs by chronic graft-versus-host disease. Genital seemed to be underestimated in chronic graft-versus-host disease organ grading (~5%).
  • The mortality-adjusted treatment rate is used to estimate the number of living patients who are receiving treatment or who will be eligible for treatment. In 2022, the 7MM mortality-adjusted treated acute graft-versus-host disease patients were ~9,830 in first-line, and these cases are expected to increase to ~11,740 cases by 2032.
This “Graft vs. Host Disease - Epidemiology Forecast - 2032” report delivers an in-depth understanding of Graft vs. Host Disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan
Study Period: 2019-2032

Graft vs. Host Disease Understanding and Diagnostic Algorithm

Graft vs. Host Disease Overview

Graft vs. Host Disease is an immune condition that occurs after transplant procedures when immune cells (T cells) from the donor (known as the graft or graft cells) attack the recipient patient host's tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant. In some cases, it can be even life-threatening. Before undergoing an allogeneic stem cell transplant, the patient will receive high doses of chemotherapy or radiation to destroy the diseased cells and prepare the body for the donor cells.

The two main types of Graft vs. Host Disease are acute Graft vs. Host Disease and Chronic Graft vs. Host Disease. As an allogeneic transplant recipient, the patient might experience either form of Graft vs. Host Disease, either form, or neither. Approximately 30-50% of people generally develop acute Graft vs. Host Disease, and 10-70% develop chronic Graft vs. Host Disease and undergo an allogeneic transplant.

Acute Graft vs. Host Disease typically starts with the sudden outbreak of a red, inflamed rash on the palms, soles, face, ears, and shoulders. The rash can often become widespread and precede the onset of gastrointestinal or liver symptoms.

Chronic Graft vs. Host Disease also tends to start with a burning rash on the same parts of the body, although it can be more severe and cause blistering, peeling, and skin hardening. Gastrointestinal and liver symptoms can also develop, in addition to symptoms affecting other organ systems, including the eyes, lungs, joints, muscles, genitals, and nervous system.

Graft vs. Host Disease diagnosis

Graft vs. Host Disease can be challenging to diagnose because many symptoms occur with other conditions or diseases, none of which have anything to do with Graft vs. Host Disease. If treated presumptively without meeting specific diagnostic criteria, a person with Graft vs. Host Disease may be exposed to therapies that are not only unnecessary but can mask the true cause of the symptoms. In cases like these, a strict set of criteria governs the diagnosis of Graft vs. Host Disease.

According to guidelines issued by the National Institutes of Health, the diagnosis of Graft vs. Host Disease typically requires at least one clinical sign of Graft vs. Host Disease paired with a confirmatory test of a pathologic feature of Graft vs. Host Disease (either involving the same or another organ). The confirmatory tests used to diagnose Graft vs. Host Disease may involve a biopsy, lab test, or imaging study. The tests may provide histological evidence of Graft vs. Host Disease (as seen by changes in cells under the microscope), serve as a biomarker of Graft vs. Host Disease (as seen by changes in lab values), or detect signs of gastrointestinal injury consistent with Graft vs. Host Disease. More than one test is sometimes needed.

Graft vs. Host Disease Epidemiology

As the market is derived using the patient-based model, the Graft-versus-host disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Hematopoietic Stem-cell Transplant Cases, Total Allogeneic Transplant Cases, Total Graft vs. Host Disease Cases by Types (Acute and Chronic), Total Incident Cases of Acute Graft vs. Host Disease by Grading and Organ Involvement, Total 5-year Prevalent Cases of Chronic Graft vs. Host Disease by Grading and Organ Involvement, Total Treated cases of Graft vs. Host Disease, and Mortality-adjusted Treated Cases of Graft vs. Host Disease in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032. The total cases of Graft vs. Host Disease in the 7MM comprised approximately 51,500 cases in 2022 and are projected to increase during the forecast period.
  • The total number of cases of Graft vs. Host Disease in the United States was around 23,100 cases in 2022.
  • The US contributed to the largest Graft vs. Host Disease population, acquiring ~45% of the 7MM in 2022. Whereas Japan accounted for around 16% and Germany accounted for around 15% of the total population share, respectively, in 2022.
  • According to the publisher's estimates, there were around 5,000 and 18,100 cases of acute and chronic Graft vs. Host Disease in the United States in 2022. These cases are projected to increase during the forecast period.

Scope of the Report

  • The report covers a segment of key events, an executive summary, and a descriptive overview of Graft vs. Host Disease, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
  • Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
  • A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.

Graft vs. Host Disease report insights

  • Patient population
  • Prevalence pattern
  • Diagnosis rate
  • Country-wise epidemiology distribution

Graft vs. Host Disease report key strengths

  • Ten years forecast
  • The 7MM coverage
  • Graft vs. Host Disease epidemiology segmentation

Graft vs. Host Disease report assessment

  • Epidemiology segmentation
  • Current diagnostic practices

Key Questions Answered

Epidemiology Insights

  • What are the disease risk and burdens of Graft vs. Host Disease? What will be the growth opportunities across the 7MM with respect to the patient population of Graft vs. Host Disease?
  • What is the historical and forecasted Graft vs. Host Disease patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
  • Why are only limited patients with symptoms treated?
  • What factors are affecting the increase in the diagnosis of symptomatic cases?

Reasons to Buy

  • The report will help develop business strategies by understanding the latest trends and changing epidemiology dynamics driving the Graft vs. Host Disease.
  • Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand the perspective of Key Opinion Leaders around the current challenges with establishing the diagnosis and current diagnosis rate of the eligible patient pool.

Table of Contents

1. Key Insights2. Report Introduction
3. Graft-versus-Host Disease: Patient Share (%) distribution
3.1. Patient Share (%) Distribution of Acute Graft-versus-Host Disease in 2019
3.2. Patient Share (%) Distribution of Acute Graft-versus-Host Disease in 2032
3.3. Patient Share (%) Distribution of Chronic Graft-versus-Host Disease in 2019
3.4. Patient Share (%) Distribution of Chronic Graft-versus-Host Disease in 2032
3.5. Patient Share (%) Distribution of Graft-versus-Host Disease in 2019
3.6. Patient Share (%) Distribution of Graft-versus-Host Disease in 2032
4. Epidemiology Methodology5. Executive Summary of Graft-versus-host Disease
6. Disease Background and Overview
6.1. Introduction
6.2. Types of Graft-versus-Host Disease
6.3. Acute Graft-versus-Host Disease
6.3.1. Staging of Acute Graft-versus-Host Disease
6.3.2. Grading of Acute
6.3.3. Signs and Symptoms of Acute Graft-versus-Host Disease
6.3.4. Risk Factors for Acute Graft-versus-Host Disease
6.3.5. Pathophysiology of Acute Graft-versus-Host Disease
6.4. Chronic Graft-versus-Host Disease
6.4.1. Classification of Chronic Graft-versus-Host Disease
6.4.2. Signs and Symptoms of Chronic Graft-versus-Host Disease
6.4.3. Risk Factors for Chronic Graft-versus-Host Disease
6.4.4. Pathophysiology of Chronic Graft-versus-Host Disease
6.5. Diagnosis of Graft-versus-Host Disease
6.5.1. Differential Diagnosis of Graft-versus-Host Disease
6.5.2. Diagnostic Algorithm
6.5.3. Diagnostic Guidelines
6.5.3.1. National Institutes of Health (NIH) and the Center for International Blood and Marrow Transplant Research (CIBMTR) Task Force position statement on standardized terminology and guidance for Graft-versus-Host Disease assessment
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale
7.3. Total Graft-versus-Host Disease Cases by Types (Acute and Chronic) in the 7MM
7.4. Epidemiology Scenario in the United States
7.4.1. Total Hematopoietic Stem-cell Transplant Cases in the United States
7.4.2. Total Allogeneic Transplant Cases in the United States
7.4.3. Total Graft-versus-Host Disease Cases by Types (Acute and Chronic) in the 7MM
7.4.4. Total Incident Cases of Acute Graft-versus-Host Disease by Grading and Organ Involvement in the United States
7.4.4.1. By Grading
7.4.4.2. By Organ Involvement
7.4.5. Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Grading and Organ Involvement in the United States
7.4.5.1. By Grading
7.4.5.2. By Organ Involvement
7.4.6. Total Treated Patients of Graft-versus-Host Disease in the United States
7.4.7. Mortality-adjusted Graft-versus-Host Disease Treated Patients in the United States
7.5. Epidemiology Scenario in EU4 and the UK
7.5.1. Total Hematopoietic Stem-cell Transplant Cases in EU4 and the UK
7.5.2. Total Allogeneic Transplant Cases in EU4 and the UK
7.5.3. Total Graft-versus-Host Disease Cases by Types (Acute and Chronic) in EU4 and the UK
7.5.4. Total Incident Cases of Acute Graft-versus-Host Disease by Grading and Organ Involvement in EU4 and the UK
7.5.4.1. By Grading
7.5.4.2. By Organ Involvement
7.5.5. Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Grading and Organ Involvement in EU4 and the UK
7.5.5.1. By Grading
7.5.5.2. By Organ Involvement
7.5.6. Total Treated Patients of Graft-versus-Host Disease in EU4 and the UK
7.5.7. Mortality-adjusted Graft-versus-Host Disease Treated Patients in EU4 and the UK
7.6. Epidemiology Scenario in Japan
7.6.1. Total Hematopoietic Stem-cell Transplant Cases in the United States
7.6.2. Total Allogeneic Transplant Cases in Japan
7.6.3. Total Graft-versus-Host Disease Cases by Types (Acute and Chronic) in Japan
7.6.4. Total Incident Cases of Acute Graft-versus-Host Disease by Grading and Organ Involvement in Japan
7.6.4.1. By Grading
7.6.4.2. By Organ Involvement
7.6.5. Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Grading and Organ Involvement in Japan
7.6.5.1. By Grading
7.6.5.2. By Organ Involvement
7.6.6. Total Treated Patients of Graft-versus-Host Disease in Japan
7.6.7. Mortality-adjusted Graft-versus-Host Disease Treated Patients in Japan
8. Appendix
8.1. Acronyms and Abbreviations
8.2. Bibliography
8.3. Report Methodology
9. Publisher Capabilities10. Disclaimer11. About the Publisher
List of Tables
Table 1: Summary of Graft-versus-Host Disease Epidemiology (2019-2032)
Table 2: Extent of Organ Involvement
Table 3: Overall Clinical Grade (based on most severe target organ involvement)
Table 4: Total Graft-versus-Host Disease Cases by Types (Acute and Chronic) in the 7MM (2019-2032)
Table 5: Total Hematopoietic Stem-cell Transplant Cases in the United States (2019-2032)
Table 6: Total Allogeneic Transplant Cases in the United States (2019-2032)
Table 7: Total Graft-versus-Host Disease Cases by Types (Acute and Chronic) in the United States (2019-2032)
Table 8: Total Incident Cases of Acute Graft-versus-Host Disease by Grading in the United States (2019-2032)
Table 9: Total Incident Cases of Acute Graft-versus-Host Disease by Organ Involvement in the United States (2019-2032)
Table 10: Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Grading in the United States (2019-2032)
Table 11: Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Organ Involvement in the United States (2019-2032)
Table 12: Total Treated Patients of Graft-versus-Host Disease in the United States (2019-2032)
Table 13: Mortality-adjusted Graft-versus-Host Disease Treated Patients in the United States (2019-2032)
Table 14: Total Hematopoietic Stem-cell transplant Cases in EU4 and the UK (2019-2032)
Table 15: Total Allogeneic Transplant cases in EU4 and the UK (2019-2032)
Table 16: Total Graft-versus-Host Disease Cases by Types (Acute and Chronic) in EU4 and the UK (2019-2032)
Table 17: Total Incident Cases of Acute Graft-versus-Host Disease by Grading in EU4 and the UK (2019-2032)
Table 18: Total Incident Cases of Acute Graft-versus-Host Disease by Organ Involvement in EU4 and the UK (2019-2032)
Table 19: Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Grading in EU4 and the UK (2019-2032)
Table 20: Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Organ Involvement in EU4 and the UK (2019-2032)
Table 21: Total Treated Patients of Graft-versus-Host Disease in EU4 and the UK (2019-2032)
Table 22: Mortality-adjusted Graft-versus-Host Disease Treated Patients in EU4 and the UK (2019-2032)
Table 23: Total Hematopoietic Stem-cell transplant Cases in Japan (2019-2032)
Table 24: Total Allogeneic Transplant cases in Japan (2019-2032)
Table 25: Total Graft-versus-Host Disease Cases by Types (Acute and Chronic) in Japan (2019-2032)
Table 26: Total Incident Cases of Acute Graft-versus-Host Disease by Grading in Japan (2019-2032)
Table 27: Total Incident Cases of Acute Graft-versus-Host Disease by Organ Involvement in Japan (2019-2032)
Table 28: Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Grading in Japan (2019-2032)
Table 29: Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Organ Involvement in Japan (2019-2032)
Table 30: Total Treated Patients of Graft-versus-Host Disease in Japan (2019-2032)
Table 31: Mortality-adjusted Graft-versus-Host Disease Treated Patients in Japan (2019-2032)
List of Figures
Figure 1: Process of Allogeneic stem cell transplantation
Figure 2: National Institutes of Health (NIH) consensus guidelines schema illustrating the classification into different types of Graft-versus-Host Disease (quality) and severity that applies to all subtypes.
Figure 3: Acute Graft-versus-Host Disease initiation phase
Figure 4: Summary of the complete pathophysiology of Acute Graft-versus-Host Disease
Figure 5: Liver Biopsy procedure
Figure 6: Diagnostic Algorithm for acute Graft-versus-Host Disease
Figure 7: Diagnostic Algorithm according to NIH
Figure 8: Diagnosis/ Workup of Graft-versus-Host Disease by National Comprehensive Cancer Network (NCCN)
Figure 9: Total Graft-versus-Host Disease Cases by Types (Acute and Chronic) in the 7MM (2019-2032)
Figure 10: Total Hematopoietic Stem-cell Transplant Cases in the United States (2019-2032)
Figure 11: Total Allogeneic Transplant Cases in the United States (2019-2032)
Figure 12: Total Graft-versus-Host Disease Cases by Types (acute and chronic) in the United States (2019-2032)
Figure 13: Total Incident Cases of Acute Graft-versus-Host Disease by Grading in the United States (2019-2032)
Figure 14: Total Incident Cases of Acute Graft-versus-Host Disease by Organ Involvement in the United States 2019-2032)
Figure 15: Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Grading in the United States (2019-2032)
Figure 16: Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Organ Involvement in the United States (2019-2032)
Figure 17: Total Treated Patients of Acute Graft-versus-Host Disease in the United States (2019-2032)
Figure 18: Total Treated Patients of Chronic Graft-versus-Host Disease in the United States (2019-2032)
Figure 19: Mortality-adjusted Acute Graft-versus-Host Disease Treated Patients in the United States (2019-2032)
Figure 20: Mortality-adjusted Chronic Graft-versus-Host Disease Treated Patients in the United States (2019-2032)
Figure 21: Total Hematopoietic Stem-cell transplant Cases in EU4 and the UK (2019-2032)
Figure 22: Total Allogeneic Transplant Cases in EU4 and the UK (2019-2032)
Figure 23: Total Graft-versus-Host Disease Cases by Types (Acute and Chronic) in EU4 and the UK (2019-2032)
Figure 24: Total Incident Cases of Acute Graft-versus-Host Disease by Grading in EU4 and the UK (2019-2032)
Figure 25: Total Incident Cases of Acute Graft-versus-Host Disease by Organ Involvement in EU4 and the UK (2019-2032)
Figure 26: Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Grading in EU4 and the UK (2019-2032)
Figure 27: Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Organ Involvement in EU4 and the UK (2019-2032)
Figure 28: Total Treated Patients of Acute Graft-versus-Host Disease in EU4 and the UK (2019-2032)
Figure 29: Total Treated Patients of Chronic Graft-versus-Host Disease in EU4 and the UK (2019-2032)
Figure 30: Mortality-adjusted Acute Graft-versus-Host Disease Treated Patients in EU4 and the UK (2019-2032)
Figure 31: Mortality-adjusted Chronic Graft-versus-Host Disease Treated Patients in EU4 and the UK (2019-2032)
Figure 32: Total Hematopoietic Stem-cell Transplant Cases in Japan (2019-2032)
Figure 33: Total Allogeneic Transplant Cases in Japan (2019-2032)
Figure 34: Total Graft-versus-Host Disease Cases by Types (Acute and Chronic) in Japan (2019-2032)
Figure 35: Total Incident Cases of Acute Graft-versus-Host Disease by Grading in Japan (2019-2032)
Figure 36: Total Incident Cases of Acute Graft-versus-Host Disease by Organ Involvement in Japan (2019-2032)
Figure 37: Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Grading in Japan (2019-2032)
Figure 38: Total 5-year Prevalent Cases of Chronic Graft-versus-Host Disease by Organ Involvement in Japan (2019-2032)
Figure 39: Total Treated Patients of Acute Graft-versus-Host Disease in Japan (2019-2032)
Figure 40: Total Treated Patients of Chronic Graft-versus-Host Disease in Japan (2019-2032)
Figure 41: Mortality-adjusted Acute Graft-versus-Host Disease Treated Patients in Japan (2019-2032)
Figure 42: Mortality-adjusted Chronic Graft-versus-Host Disease Treated Patients in Japan (2019-2032)